ATE381945T1 - Verfahren zur solubilisierung von peptid- mischungen - Google Patents

Verfahren zur solubilisierung von peptid- mischungen

Info

Publication number
ATE381945T1
ATE381945T1 AT05727232T AT05727232T ATE381945T1 AT E381945 T1 ATE381945 T1 AT E381945T1 AT 05727232 T AT05727232 T AT 05727232T AT 05727232 T AT05727232 T AT 05727232T AT E381945 T1 ATE381945 T1 AT E381945T1
Authority
AT
Austria
Prior art keywords
acid
peptide mixture
peptide mixtures
aqueous solution
solubilizing
Prior art date
Application number
AT05727232T
Other languages
English (en)
Inventor
Wolfgang Zauner
Constantia Kritsch
Christa Heinrich-Cseh
Agnes Berger
Original Assignee
Intercell Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intercell Ag filed Critical Intercell Ag
Application granted granted Critical
Publication of ATE381945T1 publication Critical patent/ATE381945T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT05727232T 2004-03-12 2005-03-11 Verfahren zur solubilisierung von peptid- mischungen ATE381945T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04450061 2004-03-12

Publications (1)

Publication Number Publication Date
ATE381945T1 true ATE381945T1 (de) 2008-01-15

Family

ID=35064441

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05727232T ATE381945T1 (de) 2004-03-12 2005-03-11 Verfahren zur solubilisierung von peptid- mischungen

Country Status (6)

Country Link
US (1) US20080145383A1 (de)
EP (2) EP1987843A3 (de)
AT (1) ATE381945T1 (de)
DE (1) DE602005004014T2 (de)
ES (1) ES2297688T3 (de)
WO (1) WO2005094891A2 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6828415B2 (en) * 1993-02-19 2004-12-07 Zentaris Gmbh Oligopeptide lyophilisate, their preparation and use
GB0716992D0 (en) 2007-08-31 2007-10-10 Immune Targeting Systems Its L Influenza antigen delivery vectors and constructs
GB0408164D0 (en) 2004-04-13 2004-05-19 Immune Targeting Systems Ltd Antigen delivery vectors and constructs
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
RU2560701C2 (ru) * 2009-05-04 2015-08-20 Эббви Байотекнолоджи Лтд. Стабильные композиции с высокими концентрациями белков антител человека против tnf-альфа
AR077384A1 (es) * 2010-07-05 2011-08-24 Eriochem Sa Una formulacion farmaceutica inyectable de melfalano.
AU2011325974B2 (en) 2010-11-11 2016-10-27 Abbvie Biotechnology Ltd. Improved high concentration anti-TNFalpha antibody liquid formulations
GB201022147D0 (en) 2010-12-31 2011-02-16 Immune Targeting Systems Its Ltd Formulation
MX342675B (es) 2011-03-10 2016-10-07 Xeris Pharmaceuticals Inc Formulaciones estables para inyeccion parenteral de farmacos de peptido.
PL2773331T3 (pl) 2011-10-31 2016-08-31 Xeris Pharmaceuticals Inc Preparaty do leczenia cukrzycy
JP6224069B2 (ja) 2012-03-23 2017-11-01 アミクローブ，インコーポレイテッド 組織適合特性を有する抗菌剤の組成物および使用
US9125805B2 (en) 2012-06-27 2015-09-08 Xeris Pharmaceuticals, Inc. Stable formulations for parenteral injection of small molecule drugs
US9018162B2 (en) 2013-02-06 2015-04-28 Xeris Pharmaceuticals, Inc. Methods for rapidly treating severe hypoglycemia
KR102428675B1 (ko) 2014-08-06 2022-08-02 엑스에리스 파머수티클스, 인크. 페이스트의 피내 및／또는 피하 주사를 위한 주사기, 키트, 및 방법
US9649364B2 (en) 2015-09-25 2017-05-16 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic formulations in aprotic polar solvents
US11590205B2 (en) 2015-09-25 2023-02-28 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents
WO2018187617A1 (en) * 2017-04-06 2018-10-11 Amicrobe, Inc. Compositions and uses of locally applied antimicrobials with enhanced performance and safety
ES2982668T3 (es) 2017-06-02 2024-10-17 Xeris Pharmaceuticals Inc Formulaciones de fármacos de moléculas pequeñas resistentes a la precipitación

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05112464A (ja) * 1991-04-09 1993-05-07 Sanwa Kagaku Kenkyusho Co Ltd 安定化された ［Ｌｅｕ１３−ｍｏｔｉｌｉｎ−Ｈｓｅ 医薬組成物
NZ243090A (en) * 1991-06-18 1993-11-25 Lilly Co Eli Method of identifying active peptides and synthesis of peptide mixtures with a known amino acid in the last coupled position
DE4305225A1 (de) 1993-02-19 1994-08-25 Asta Medica Ag Neues Herstellverfahren für Cetrorelix Lyophilisat
US6828415B2 (en) 1993-02-19 2004-12-07 Zentaris Gmbh Oligopeptide lyophilisate, their preparation and use
EP0788370A4 (de) * 1993-07-09 1998-07-08 Smithkline Beecham Corp Zyklische, teilzufallige peptidbibliotheken
DE4402756A1 (de) * 1994-01-31 1995-08-03 Boehringer Mannheim Gmbh Spezifische Bindungssubstanzen für Antikörper und deren Verwendung für Immunoassays oder Vakzine
CO4600681A1 (es) 1996-02-24 1998-05-08 Boehringer Ingelheim Pharma Composicion farmaceutica para la modulacion inmunitaria
US5980898A (en) * 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
KR20000070338A (ko) * 1997-01-20 2000-11-25 나가시마 카쭈시게, 노미야마 아키히코 펩티드의 안정화 방법 및 당해 방법을 이용한 펩티드 함유 동결건조 의약조성물
DE19803453A1 (de) 1998-01-30 1999-08-12 Boehringer Ingelheim Int Vakzine
US20020019061A1 (en) * 1999-08-31 2002-02-14 Hung-Sen Lai Purification and analysis of cyclic peptide libraries, and compositions thereof
AT408721B (de) * 1999-10-01 2002-02-25 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung enthaltend ein antigen
WO2001047554A1 (fr) * 1999-12-28 2001-07-05 Chugai Seiyaku Kabushiki Kaisha Compositions d'anticorps stables et preparations pour injection
DE10024451A1 (de) * 2000-05-18 2001-11-29 Asta Medica Ag Pharmazeutische Darreichungsform für Peptide, Verfahren zu deren Herstellung und Verwendung
WO2002013857A2 (en) 2000-08-17 2002-02-21 Intercell Biomedizinische Forschungs- Und Entwicklungs Ag A vaccine which comprises at least one antigen and a cathelididin derived antimicrobial peptide or a derivative thereof
AT410635B (de) 2000-10-18 2003-06-25 Cistem Biotechnologies Gmbh Vakzin-zusammensetzung
GB0218821D0 (en) * 2002-08-13 2002-09-18 Glaxosmithkline Biolog Sa Novel compositions
WO2004024182A2 (en) * 2002-09-13 2004-03-25 Intercell Ag Method for isolating hepatitis c virus peptides
ATE489967T1 (de) * 2003-07-11 2010-12-15 Intercell Ag Hcv-vakzin

Also Published As

Publication number Publication date
ES2297688T3 (es) 2008-05-01
DE602005004014D1 (de) 2008-02-07
EP1722819B1 (de) 2007-12-26
EP1987843A3 (de) 2011-10-26
WO2005094891A2 (en) 2005-10-13
US20080145383A1 (en) 2008-06-19
EP1722819A2 (de) 2006-11-22
DE602005004014T2 (de) 2008-12-11
EP1987843A2 (de) 2008-11-05
WO2005094891A3 (en) 2006-03-16

Similar Documents

Publication Publication Date Title
ATE381945T1 (de) Verfahren zur solubilisierung von peptid- mischungen
Swinnen et al. Facile, Fmoc-compatible solid-phase synthesis of peptide C-terminal thioesters
Frohman et al. Dipeptidylpeptidase IV and trypsin-like enzymatic degradation of human growth hormone-releasing hormone in plasma.
ATE551423T1 (de) Sequenzen von hepatitis c virus-genotypen sowie ihre verwendungen als therapeutika und diagnostika
ATE417925T1 (de) Verfahren zur präsentation von (poly)peptiden/proteinen auf bakteriophagenpartikeln via disulfidbindungen
PT948541E (pt) Analogos da pthrp
DE60311731D1 (de) Verfahren zur rekombinanten Herstellung von Antifusogenikpeptide
DK0929574T3 (da) Modulatorer af beta-amyloidpeptidaggregering, som omfatter D-aminosyrer
DK1961811T3 (da) Cytokinligand til behandling af asthma og luftvejs-hyper-responsivitet
DE60320362D1 (de) Verfahren zur Herstellung von Dipeptiden
ATE429920T1 (de) Pharmazeutische zusammensetzung und verfahren zur behandlung von hypogonadismus
WO2002002627A3 (en) Interferon-like protein zcyto21
JP2002530430A (ja) Ｃ型肝炎ウイルスｎｓ３プロテアーゼ阻害用の医薬組成物
DE69723485D1 (de) Verfahren zur Identifizierung von Wirkstoffen gegen HCV durch Verwendung von Strukturkoordinaten der Hepatitis-C-Virus-Protease
DE59209512D1 (de) Hcv peptidantigene und verfahren zur bestimmung von hcv
DK1201137T3 (da) Cystein-/glycinrige peptider
ATE390190T1 (de) Verfahren zur extraktion von inhaltsstoffen aus organischem material
ATE260972T1 (de) Verfahren zur aktivierung von denaturiertem protein
DE60034117D1 (de) Verfahren zur herstelllung von gonadotropin-zusammensetzungen
NO991198D0 (no) FremgangsmÕte ved fremstilling av et plasmaproteinholdig legemiddel
DE60024821D1 (de) Verfahren zur reinigung von aldehydverunreinigungen
WO2004014936A3 (fr) Melange de peptides issus des proteines c et ns3 du virus de l'hepatite c et leurs applications.
ATE516306T1 (de) Verbessertes verfahren zur reinigung von tfpi und tfpi-analogen
KR980002263A (ko) C형 간염 바이러스의 프로테아제의 활성을 측정할 수 있는 c형 간염 대체 바이러스, 그 재조합 유전자 및 그 용도
Abiko et al. Chemical syntheses of CART (human, 55-102) analogues and their anorectic effect on food intake in rats induced by neuropeptide Y

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1722819

Country of ref document: EP